Vaxxinity (VAXX) News Today $0.0001 -0.02 (-99.50%) As of 10/13/2025 02:25 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock VAXX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Brain healthOctober 24, 2024 | newsweek.comNTreatment Trials in Alzheimer's DiseaseSeptember 30, 2024 | msn.comVaxxinity UB-312 Parkinson's Trial Results Published in Nature MedicineJune 20, 2024 | globenewswire.comWhy Is Vaxxinity (VAXX) Stock Up 39% Today?May 3, 2024 | investorplace.comWhy Is Vaxxinity (VAXX) Stock Down 58% Today?April 22, 2024 | investorplace.comVaxxinity Plans to Delist Shares From NasdaqApril 19, 2024 | marketwatch.comVaxxinity Issues Shareholder LetterApril 19, 2024 | globenewswire.comVaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common StockApril 19, 2024 | globenewswire.comVaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual MeetingMarch 28, 2024 | globenewswire.comVAXX Stock Earnings: Vaxxinity Beats EPS for Q4 2023March 27, 2024 | investorplace.comVaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate UpdatesMarch 27, 2024 | globenewswire.comVaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD™ 2024March 7, 2024 | globenewswire.comVaxxinity’s Heart Health Innovation to Reduce LDL Cholesterol LevelsFebruary 15, 2024 | finance.yahoo.comVaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data PublishedFebruary 15, 2024 | finance.yahoo.comVaxxinity's Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data PublishedFebruary 15, 2024 | globenewswire.comVaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024February 13, 2024 | finance.yahoo.comVaxxinity (NASDAQ:VAXX) Shares Down 2.2% February 8, 2024 | marketbeat.comVaxxinity, UF Join Forces Against Neurodegenerative DiseasesJanuary 30, 2024 | finance.yahoo.comVaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of FloridaJanuary 30, 2024 | finance.yahoo.comVaxxinity & UCF to Collaborate on Space Medicine ResearchJanuary 19, 2024 | finance.yahoo.comVaxxinity Announces Collaboration on Space Medicine Research with University of Central FloridaJanuary 18, 2024 | finance.yahoo.comVaxxinity to Present at the 2024 J.P. Morgan Healthcare ConferenceJanuary 3, 2024 | finance.yahoo.comThe Zacks Analyst Blog Highlights Biogen, Prothena, AC Immune's and VaxxinityDecember 12, 2023 | finance.yahoo.comAlzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And OthersNovember 21, 2023 | markets.businessinsider.comSeveral Alzheimer's vaccines enter clinical trials amid breakthrough treatments' successNovember 20, 2023 | foxnews.comResearchers return to Alzheimer's vaccines, buoyed by recent drug successNovember 20, 2023 | msn.comVaxxinity to Present at Upcoming November Medical and Investor ConferencesNovember 13, 2023 | finance.yahoo.comVaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 8, 2023 | finance.yahoo.comPrivate companies invested in Vaxxinity, Inc. (NASDAQ:VAXX) copped the brunt of last week's US$41m market cap declineOctober 10, 2023 | finance.yahoo.comMovers Lab Fund I. Lp Prime Sells 25,089 Shares of Vaxxinity, Inc. (NASDAQ:VAXX) StockSeptember 8, 2023 | marketbeat.comDown -22.18% in 4 Weeks, Here's Why You Should You Buy the Dip in Vaxxinity, Inc. (VAXX)September 7, 2023 | finance.yahoo.comVaxxinity Says UB-311 Shows Potential Advancements in Alzheimer’s TreatmentAugust 11, 2023 | finance.yahoo.comVaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s DiseaseAugust 10, 2023 | finance.yahoo.comVaxxinity Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 9, 2023 | finance.yahoo.comVaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific DirectorJuly 28, 2023 | finance.yahoo.comVaxxinity Appoints Dr. Peter Powchik as Global Scientific DirectorJuly 28, 2023 | finance.yahoo.comLincoln National Corp Invests $93,000 in Vaxxinity, Inc. (NASDAQ:VAXX)July 28, 2023 | marketbeat.comPromising Milestone in Neurodegenerative Disease Treatment: Vaxxinity’s UB-312 in Parkinson’s PatientsJuly 17, 2023 | finance.yahoo.comVaxxinity Demonstrates Target Engagement of Toxic Alpha-Synuclein in Parkinson’s PatientsJuly 17, 2023 | finance.yahoo.comMcAdam LLC Buys New Stake in Vaxxinity, Inc. (NASDAQ:VAXX)July 9, 2023 | marketbeat.comPositive Phase 1 Results: Vaxxinity’s UB-312 Shows Promise in Parkinson’s DiseaseJune 22, 2023 | finance.yahoo.comVaxxinity Touts Encouraging Data From Early-Stage Parkinson's Vaccine TrialJune 22, 2023 | finance.yahoo.comVaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson’s DiseaseJune 22, 2023 | finance.yahoo.comVaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 9, 2023 | finance.yahoo.comVaxxinity, Inc.'s (NASDAQ:VAXX) biggest owners are private companies who got richer after stock soared 23% last weekMay 3, 2023 | finance.yahoo.comWeekly Biotech Pulse: Vaxxinity results, Biogen's FDA review, and more | Pro RecapApril 24, 2023 | finance.yahoo.comVaxxinity to Present at World Vaccine Congress, American Academy of Neurology, and BNA2023 Festival of Neuroscience in AprilMarch 28, 2023 | finance.yahoo.comVaxxinity Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate UpdatesMarch 27, 2023 | finance.yahoo.comVaxxinity Joins TransCelerate Research and Development ConsortiumMarch 21, 2023 | finance.yahoo.comVaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of VXX-401, Investigational Anti-PCSK9 Vaccine to Treat HypercholesterolemiaMarch 20, 2023 | finance.yahoo.com Get Vaxxinity News Delivered to You Automatically Sign up to receive the latest news and ratings for VAXX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VAXX Media Mentions By Week VAXX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VAXX News Sentiment▼0.000.75▲Average Medical News Sentiment VAXX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VAXX Articles This Week▼00▲VAXX Articles Average Week Get the Latest News and Ratings for VAXX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Vaxxinity and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies NKGen Biotech News Today Virpax Pharmaceuticals News Today Trevena News Today Ainos News Today BriaCell Therapeutics News Today Curanex Pharmaceuticals News Today CytoMed Therapeutics News Today enGene News Today Fortress Biotech News Today Galapagos News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VAXX) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersThe Army Just Got a New Drone SupplierA cutting-edge drone developer just secured a U.S. Army deal to supply its Flex FPV Modular Drones and build a...The Tomorrow Investor | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredWhat if your job didn’t matter — and neither did China’s chip ban?If you’ve been watching the headlines lately…You’ve seen how Nvidia and AMD just got the green light to resume...Timothy Sykes | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredNvidia CEO shares biggest regret?Earlier this year I predicted that the only reason Elon was in Washington was to push an AI-first agenda. Sinc...Altimetry | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredWhat Wall Street Won’t Say Out LoudDiscover the 7 key indicators before everyone else doesAmerican Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxxinity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxxinity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
